The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Whole blood transcriptomics analysis of 24h responses to bevacizumab/erlotinib in nonsquamous non-small cell lung cancer: A multicenter phase II trial SAKK19/05.
F. Baty
No relevant relationships to disclose
M. Frueh
No relevant relationships to disclose
S. Crowe
No relevant relationships to disclose
K. J. Na
No relevant relationships to disclose
C. Droege
No relevant relationships to disclose
D. C. Betticher
Consultant or Advisory Role - Roche
R. Cathomas
Consultant or Advisory Role - Roche
F. Zappa
Consultant or Advisory Role - Roche
M. Pless
Consultant or Advisory Role - Roche
M. H. Brutsche
Honoraria - Roche